Current Vaccine Clinical Studies
We are currently enrolling volunteers for a range of studies. If you are interested in volunteering to participate in a clinical trial, please call us at 1-866-833-LIFE (5433) or e-mail us at vaccines@nih.gov.
Studies Open to Accrual
These studies are recruiting.
VRC Clinical Trials Related to Development of Vaccines for Prevention of HIV
VRC 000 (02-I-0127):
Screening Subjects for HIV Vaccine Research Studies
VRC 012 (07-I-0167):
A Phase I Clinical Trial of the Safety and Immunogenicity of an HIV-1 Adenoviral Vector Serotype 35 Vaccine, VRC-HIVADV027-00-VP (rAd35-EnvA): Dose Escalation as a Single Agent and Prime-Boost Schedules with an HIV-1 Adenoviral Vector Serotype 5 Vaccine, VRC-HIVADV038-00-VP (rAd5-EnvA), in Uninfected Adults
VRC 015 (08-I-0171):
A Phase I, Open-Label Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of a Multiclade Recombinant HIV-1 Adenoviral Vector Vaccine, VRC-HIVADV014-00-VP, in Uninfected Adults Randomized to Needle or Biojector Methods of Intramuscular Injection
HVTN 505 (09-I-0163):
Phase 2, randomized, placebo-controlled trial to evaluate the safety and effect on post-HIV acquisition viremia of a multiclade HIV-1 DNA plasmid vaccine followed by a multiclade HIV-1 recombinant adenoviral vector vaccine in HIV-uninfected, adenovirus type 5 neutralizing antibody negative, circumcised men
VRC Clinical Trials Related to Vaccines for Biodefense and Emerging Pathogens
VRC 300 (03-I-0285):
Screening of Healthy Volunteers for Clinical Trials of Investigational Vaccines to Prevent Infectious Diseases
VRC 206 (08-I-0065)
A Phase I Study to Evaluate the Safety and Immunogenicity of an Ebola DNA Plasmid Vaccine, VRC-EBODNA023-00-VP, and a Marburg DNA Vaccine, VRC-MARDNA025-00-VP, in Healthy Adults
VRC 306 (09-I-0012):
An Open-Label, Randomized Phase I Study in Healthy Adults of Four Prime-Boost Schedules with Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005 (Sanofi Pasteur, Inc), Administered Alone or Following Recombinant DNA Plasmid (H5) Vaccine, VRC-AVIDNA036-00-VP (VRC, NIAID)
VRC 307 (09-I-0090):
A Double-Blind, Randomized Phase I Study of the Safety and Immunogenicity of a Prime-Boost Schedule of the Investigational DNA Trivalent Influenza Vaccine, VRC-FLUDNA047-00-VP, Followed by the 2008/2009 Seasonal Influenza Trivalent Inactivated Vaccine (TIV) Compared to TIV Alone in Healthy Adults Ages 18-50 and 51-70 Years
These studies are not recruiting.
VRC Protocols to Obtain Laboratory Samples for Vaccine and Immunology Research
VRC 200 (03-I-0263):
Apheresis Procedures to Obtain Plasma or Peripheral Blood Mononuclear Cells (PBMCs) for Research Studies
back to top